Acurx granted new patent for ibezapolstat to treat CDI

Acurx announced that a new patent has been granted by the USPTO on July 16 relating to ibezapolstat and its use to treat C. difficile Infection – CDI – while reducing the recurrence of the infection, as well as improving the health of the gut microbiome. This is the latest in the series of granted patents and pending patent applications that Acrux has filed to protect its proprietary technologies in the field of antimicrobials. Acurx previously had a successful FDA End-of- Phase 2 Meeting and Phase 3 Readiness for ibezapolstat for the Treatment of C. difficile Infection. Agreement with FDA was reached on key elements to move forward with its international Phase 3 clinical trial program. Agreement was also reached with FDA on the complete non-clinical and clinical development plan for filing of a New Drug Application for marketing approval. Planning continues to advance ibezapolstat into international Phase 3 clinical trials for treatment of C. difficile Infection. Acurx is also now preparing to submit requests for guidance to initiate clinical trials in the EU, the UK, Japan and Canada.